



0311-02

1644 #8

Express Mail Mailing Label No. EV072530419US

TRANSMITTAL  
FORM

Application Serial Number	09/780,668
Filing Date	February 9, 2001
First Named Inventor	Gillies
Group Art Unit	1644
Examiner Name	M. Jamroz
Attorney Docket No.	LEX-011
Patent No.	Not applicable
Issue Date	Not applicable

TECH CENTER 1600/2900

MAR 15 2002

RECEIVED


## ENCLOSURES (check all that apply)

- |  |  |  |
|--|--|--|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Check Attached<br><input type="checkbox"/> Copy of Fee Transmittal Form<br><input checked="" type="checkbox"/> Amendment/Response<br><input type="checkbox"/> Preliminary<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____]<br><input type="checkbox"/> Petition for Extension of Time<br><input type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Form PTO-1449<br><input type="checkbox"/> Copies of IDS Citations<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Sequence Listing submission<br><input type="checkbox"/> Paper Copy/CD<br><input type="checkbox"/> Computer Readable Copy<br><input type="checkbox"/> Statement verifying identity of above | <input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553)<br><input type="checkbox"/> Formal Drawing(s)<br><input type="checkbox"/> Request For Continued Examination (RCE) Transmittal<br><input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application<br><input type="checkbox"/> Small Entity Statement<br><input type="checkbox"/> CD(s) for large table or computer program<br><input type="checkbox"/> Amendment After Allowance<br><input type="checkbox"/> Request for Certificate of Correction<br><input type="checkbox"/> Certificate of Correction (in duplicate) | <input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences<br><input type="checkbox"/> Appeal Brief (in triplicate)<br><input type="checkbox"/> Status Inquiry<br><input checked="" type="checkbox"/> Return Receipt Postcard<br><input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8<br><input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8<br><input type="checkbox"/> Additional Enclosure(s) (please identify below) |
|--|--|--|

## CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator  
Testa, Hurwitz & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110  
Tel. No.: (617) 248-7000  
Fax No.: (617) 248-7100

## SIGNATURE BLOCK

Respectfully submitted,  
  
Date: March 8, 2002  
Reg. No. 41,640  
Tel. No.: (617) 248-7012  
Fax No.: (617) 248-7100  
Michael H. Brodowski  
Atty/Agent for Applicant(s)  
Testa, Hurwitz & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110



Express Mail Mailing Label No. EV072530419US

*Election / #8*  
*3/21/02*

PATENT  
Attorney Docket No. LEX 11

TECH CENTER 1600/2900

MAR 15 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies et al.  
SERIAL NUMBER: 09/780,668 GROUP NUMBER: 1644  
FILING DATE: February 9, 2001 EXAMINER: M. Jamroz  
TITLE: ENHANCING THE CIRCULATING HALF-LIFE OF  
ANTIBODY-BASED FUSION PROTEINS

Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

In the Office action mailed from the U.S. Patent Office on February 11, 2002, restriction of the claims to one of the following groups is required for the above-identified patent application. Group I, claims 1-19, 24-41, 43, and 45-47, is drawn to an antibody-based fusion protein; Group II, claims 20-23, is drawn to a method of increasing the circulating half-life of an antibody-based fusion protein comprising mutating an amino acid near a junction point; Group III, claim 42, is drawn to a method of identifying a mutation that increases the circulating half life of an antibody-based fusion protein by comparing a non-mutated fusion protein and a mutated fusion protein; and Group IV, claim 44, is drawn to a method treating a disease comprising administering an antibody-based fusion protein.


Applicants provisionally elect with traverse to prosecute Group I, i.e., claims 1-19, 24-41, 43, and 45-47.

If the Examiner believes a conversation with Applicant's attorney would be helpful in

Response to Restriction Requirement  
U.S. Serial No. 09/780,668  
Page 2 of 2

expediting prosecution of this application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



Michael H. Brodowski  
Registration No. 41,640

Dated: March 8, 2002  
TESTA, HURWITZ & THIBEAULT, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110  
Tel: (617) 248-7012  
Fax: (617) 248-7100

2301873\_1